<DOC>
	<DOC>NCT03100318</DOC>
	<brief_summary>FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.</brief_summary>
	<brief_title>Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Benzbromarone</mesh_term>
	<criteria>Hyperuricemic or gout patients Serum urate level: &gt;= 7.0mg/dL in patients with history of gout, or &gt;= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or &gt;= 9.0mg/dL Gouty arthritis within two weeks before start of study treatment Secondary hyperuricemia HbA1c: &gt;= 8.4% Uric acidoverproduction type in the classification of hyperuricemia History of, clinically significant cardiac, hematologic and hepatic disease Kidney calculi or clinically significant urinary calculi Hepatic dysfuction, or AST: &gt;=100 IU/L or ALT: &gt;=100 IU/L at the preexamination eGFR: &lt; 30mL/min/1.73m^2 Systolic blood pressure: &gt;= 180 mmHg Diastolic blood pressure: &gt;= 110 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>